Catalog4 refs
Mazdutide (IBI362)
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
CirculationSkin
Overview
First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.
Primary Uses
Severe Obesity Management
Metabolic Syndrome Improvement
Liver Fat Reduction
Glycemic Control
Dual Endpoint Achievement
Blood Pressure Reduction
Lipid Profile Enhancement
Protocol Reference
Dose
Start 1.5-3mg weekly, titrate up to 6-9mg based on response
Frequency
Once weekly
Half-life
6-8 days
Route
Subcutaneous injection
Evidence
Extensively Studied
Research Models
Human
Also in Metabolic